Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 201–300 of 1,000
Cromer, M. K., Camarena, J., Martin, R. M., Lesch, B. J., Vakulskas, C. A., Bode, N. M., Kurgan, G., Collingwood, M. A., Rettig, G. R., Behlke, M. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01284-y · Cited by 82
Hierarchical organization of fetal and adult hematopoietic stem cells
Babovic, S., & Eaves, C. J. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.005 · Cited by 74
β-Thalassemia intermedia: a comprehensive overview and novel approaches
Asadov, C. D., Alimirzoyeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2411-9 · Cited by 94
Song, L., Kauss, M. A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G. R., Rivers, A. E., Aslanidi, G. V., Ling, C., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.04.003 · Cited by 80
“Indeed, in a recent clinical trial, a recombinant lentiviral vector-mediated β -globin gene transfer in an adult patient with severe β-thalassaemia led to transfusion-independence [1].”
Counting stem cells: methodological constraints
Bystrykh, L. V., Verovskaya, E. V., Zwart, E., Broekhuis, M., & de Haan, G. (2012) · Nature Methods · doi:10.1038/nmeth.2043 · Cited by 80
Scaramuzza, S., Biasco, L., Ripamonti, A., Castiello, M. C., Loperfido, M., Draghici, E., Hernandez, R. J., Benedicenti, F., Radrizzani, M., Salomoni, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.23 · Cited by 77
Recent trends in the gene therapy of β-thalassemia
Gambari, R., Finotti, A., Breda, L., Lederer, C. W., Bianchi, N., Zuccato, C., Klenathous, M., & Rivella, S. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s46256 · Cited by 106
“The first successful gene therapy trial for β -thalassemia 85 was reported in the manuscript published by Cavazzana-Calvo et al in 2010 87 and commented on by Kaiser.”
Clinical Applications of Gene Therapy for Primary Immunodeficiencies
Cicalese, M. P., & Aiuti, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.047 · Cited by 83
Urchin-like ceria nanoparticles for enhanced gene therapy of osteoarthritis
Chen, H., Tianwen, Y., Hu, F., Chen, K., Li, B., Qiu, M., Chen, Z., Sun, Y., Ye, W., Wang, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf0988 · Cited by 90
Hematopoietic stem cell engineering at a crossroads
Rivière, I., Dunbar, C. E., & Sadelain, M. (2012) · Blood · doi:10.1182/blood-2011-09-349993 · Cited by 54
“insulators (24,141) Dominant, myeloid-biased cell”
Heffner, G. C., Bonner, M., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 72
“VCN was assessed relative to the Clone K3 cDNA, known to contain two copies of integrated viral DNA per cell.(2)”
MethodThe forces driving clonal expansion of the HIV-1 latent reservoir
Liu, R., Simonetti, F. R., & Ho, Y. (2020) · Virology Journal · doi:10.1186/s12985-019-1276-8 · Cited by 93
“In an example of lentiviral vector mediated gene therapy for β-thalassemia, the lentiviral vector encoding β-globin integrated in the same orientation of the transcription regulator HMGA2 gene, disrupted HMGA2-mediated transcriptional regulation, and caused clonal expansion of this T cell clone [91].”
BackgroundProduction of CGMP-Grade Lentiviral Vectors.
Ausubel, L. J., Hall, C., Sharma, A., Shakeley, R., Lopez, P., Quezada, V., Couture, S., Laderman, K., McMahon, R., Huang, P., et al. (2012) · PubMed · Cited by 109
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 83
Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration
Cooper, A. R., Patel, S., Senadheera, S., Plath, K., Kohn, D. B., & Hollis, R. P. (2011) · Journal of Virological Methods · doi:10.1016/j.jviromet.2011.06.019 · Cited by 76
A new generation of human artificial chromosomes for functional genomics and gene therapy
Kouprina, N., Earnshaw, W. C., Masumoto, H., & Larionov, V. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1113-3 · Cited by 81
Transposons: Moving Forward from Preclinical Studies to Clinical Trials
Tipanee, J., VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.128 · Cited by 77
Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives
Staal, F. J. T., Aiuti, A., & Cavazzana, M. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00443 · Cited by 81
Family-directed umbilical cord blood banking
Gluckman, É., Ruggeri, A., Rocha, V., Baudoux, É., Boo, M. J., Kurtzberg, J., Welte, K., Navarrete, C., & van Walraven, S. M. (2011) · Haematologica · doi:10.3324/haematol.2011.047050 · Cited by 76
“Follow up in months, median (range) 48 (3-248)”
BackgroundLentiviral vector bioprocess economics for cell and gene therapy commercialization
Comisel, R.-M., Kara, B., Fiesser, F. H., & Farid, S. S. (2020) · Biochemical Engineering Journal · doi:10.1016/j.bej.2020.107868 · Cited by 82
Advances in Lentivirus Purification
Moreira, A. S., Cavaco, D. G., Faria, T. Q., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020) · Biotechnology Journal · doi:10.1002/biot.202000019 · Cited by 78
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Di Micco, R., Kajaste-Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.014 · Cited by 70
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers
Richard, F., van Lier, J. J., Roubert, B., Haboubi, T., Göhring, U., & Dürrenberger, F. (2020) · American Journal of Hematology · doi:10.1002/ajh.25670 · Cited by 72
Generation of an HIV resistant T-cell line by targeted “stacking” of restriction factors
Voit, R. A., McMahon, M. A., Sawyer, S. L., & Porteus, M. H. (2013) · Molecular Therapy · doi:10.1038/mt.2012.284 · Cited by 74
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
“In addition, a partially dominant cell clone bearing an integration site within the HMGA2 gene in a β-thalassaemia’s Boris Kantor et al.92 clinical trial raised anxiety among observers about the possibility of cancer development (Cavazzana-Calvo et al., 2010).”
BackgroundCurrent status of haemophilia gene therapy
High, K. H., Nathwani, A., Spencer, T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 73
What Integration Sites Tell Us about HIV Persistence
Hughes, S. H., & Coffin, J. M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.04.010 · Cited by 80
Adult mesenchymal stem cells and their potency in the cell-based therapy.
Das, M., Sundell, I. B., & Koka, P. S. (2013) · PubMed · Cited by 85
Cesana, M., Guo, M. H., Cacchiarelli, D., Wahlster, L., Barragan, J., Doulatov, S. R., Vo, L. T., Salvatori, B., Trapnell, C., Clement, K., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.03.012 · Cited by 87
“, 1995) as the result of chromosomal rearrangements, and in gene therapy trials, as a consequence of insertional mutagenesis that dissociate the HMGA2 3’UTR from its protein-coding region (Cavazzana-Calvo et al., 2010).”
BackgroundHMGA Proteins in Stemness and Differentiation of Embryonic and Adult Stem Cells
Parisi, S., Piscitelli, S., Passaro, F., & Russo, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010362 · Cited by 81
“Indeed, the therapeutic benefit obtained by lentiviral β-globin gene transfer in an adult patient with severe βE/β0-thalassaemia was correlated to the transcriptional activation of HMGA2 mRNA in erythroid stem/progenitor cells, which is accompanied by a benign cell expansion [46].”
BackgroundA method to sequence and quantify DNA integration for monitoring outcome in gene therapy
Brady, T., Roth, S. L., Malani, N., Wang, G. P., Berry, C. C., Leboulch, P., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Papapetrou, E. P., Sadelain, M., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr140 · Cited by 71
“We tested this in a sample from a b-thalassemia gene therapy trial, in which a cell harbouring a single vector integration site in the HMGA2 gene expanded to comprise more than one-third of the gene-corrected peripheral blood mononuclear cells (PBMC) population, as documented by quantitative PCR assays (8).”
BackgroundMethodSelf-citationWolstein, O., Boyd, M. P., Millington, M., Impey, H., Boyer, J., Howe, A., Delebecque, F., Cornetta, K. G., Rothe, M., Baum, C., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.11 · Cited by 82
Self-citationCure for thalassemia major – from allogeneic hematopoietic stem cell transplantation to gene therapy
Srivastava, A., & Velayudhan, S. R. (2016) · Haematologica · doi:10.3324/haematol.2015.141200 · Cited by 81
Brendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
“The titer of this vector in pilot production runs was lower than desired, which prompted us to test the therapeutic shRNA cassette in an alternative LVV backbone, which was previously used in clinical trials.(26,29) Similar to the research vector, this optimized self-inactivating (SIN) third generation LVV BCH-BB694 e…”
MethodMilani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72
“Whereas several ongoing clinical trials support the efficacy and safety of LV for ex vivo gene therapy (Cartier et al, 2009; Cavazzana-Calvo et al, 2010; Aiuti et al, 2013; Biffi et al, 2013; Maude et al, 2014), in vivo liver-directed gene therapy with LV remains more challenging.”
BackgroundRonen, K., Negre, O., Roth, S., Colomb, C., Malani, N., Denaro, M., Brady, T., Fusil, F., Gillet-Legrand, B., Hehir, K., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.20 · Cited by 71
Self-citationProgress and prospects of gene therapy clinical trials for the muscular dystrophies
Bengtsson, N. E., Seto, J. T., Hall, J. K., Chamberlain, J. S., & Odom, G. L. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv420 · Cited by 70
van Til, N. P., Sarwari, R., Visser, T. P., Hauer, J., Lagresle‐Peyrou, C., van der Velden, G., Malshetty, V. S., Cortés, P., Jollet, A., Danos, O., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.009 · Cited by 74
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
Clinical applications of gene therapy for rare diseases: A review
Papaioannou, I., Owen, J. S., & Yáñez‐Muñoz, R. J. (2023) · International Journal of Experimental Pathology · doi:10.1111/iep.12478 · Cited by 79
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies
Blaeschke, F., Chen, Y. Y., Apathy, R., Dániel, B., Chen, A. Y., Chen, P. A., Sándor, K., Zhang, W., Li, Z., Mowery, C. T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.013 · Cited by 74
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
Thalassemia: An Overview of 50 Years of Clinical Research
Sankaran, V. G., & Nathan, D. G. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.08.009 · Cited by 80
“Nonetheless, there is promise that such approaches may become a clinical reality in the near future.(122) Improvements in vector design, viral transduction protocols, use of various target cell populations, and monitoring of patients suggests that these approaches are becoming safer and more effective.”
BackgroundIn vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia
Wang, H., Georgakopoulou, A., Psatha, N., Li, C., Capsali, C., Samal, H. B., Anagnostopoulos, Α., Ehrhardt, A., Izsvák, Z., Papayannopoulou, T., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122836 · Cited by 71
Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice
Dahl, M., Doyle, A., Olsson, K., Månsson, J.-E., Marques, A. R. A., Mirzaian, M., Aerts, J. M., Ehinger, M., Rothe, M., Modlich, U., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.16 · Cited by 67
Developmental regulation of myeloerythroid progenitor function by the Lin28b–let-7–Hmga2 axis
Rowe, R. G., Wang, L. D., Coma, S., Han, A., Mathieu, R., Pearson, D. S., Ross, S., Sousa, P., Nguyen, P. T., Rodriguez, A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151912 · Cited by 67
“Interestingly, this effect parallels a study wherein insertional activation of HMGA2 by a gene therapy lentivirus in a human β-thalassemia patient resulted in autonomous erythropoiesis and transfusional independence (Cavazzana-Calvo et al., 2010).”
Background2021 update on clinical trials in β‐thalassemia
Musallam, K. M., Bou‐Fakhredin, R., Cappellini, M. D., & Taher, A. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26316 · Cited by 74
Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease
Fitzhugh, C. D., Abraham, A., Tisdale, J. F., & Hsieh, M. M. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.08.014 · Cited by 67
The stability of envelope-pseudotyped lentiviral vectors
Dautzenberg, I. J. C., Rabelink, M. J. W. E., & Hoeben, R. C. (2020) · Gene Therapy · doi:10.1038/s41434-020-00193-y · Cited by 69
Recent advances in lentiviral vectors for gene therapy
Wang, X., Ma, C., Rodríguez‐Labrada, R., Qin, Z., Xu, T., He, Z., & Wei, Y. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1952-5 · Cited by 68
Gene Editing and Genotoxicity: Targeting the Off-Targets
Blattner, G., Cavazza, A., Thrasher, A. J., & Turchiano, G. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.613252 · Cited by 70
“…accepted that most of the indels fall in a size spectrum of under 50 bp (KoikeYusa et al., 2014; van Overbeek et al., 2016), it has been shown that genome editing can also lead to large deletions of several kilobases (kb) (Kosicki et al., 2018; Chakrabarti et al., 2019; Turchiano et al., 2020).”
BackgroundAdvances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases
Singh, K., Sethi, P., Datta, S., Chaudhary, J. S., Kumar, S., Jain, D., Gupta, J. K., Kumar, S., Guru, A., & Panda, S. P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102321 · Cited by 72
Gene therapy for primary immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., Touzot, F., & Cavazzana, M. (2015) · Clinical Genetics · doi:10.1111/cge.12576 · Cited by 67
“It is noteworthy that in the meantime, LV vectors have been used clinically to modify HSCs from patients with other inherited disorders, including adrenoleukodystrophy (58), metachromatic leukodystrophy (52) and β thalassemia (59).”
BackgroundSelf-citationGene Therapy for Hemoglobinopathies
Chandrakasan, S., & Malik, P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.12.003 · Cited by 62
Astrakhan, A., Sather, B. D., Ryu, B. Y., Khim, S., Singh, S., Humblet-Baron, S., Ochs, H. D., Miao, C. H., & Rawlings, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-340711 · Cited by 63
Clinical management of adult sickle-cell disease
Bartolucci, P., & Galactéros, F. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328351c35f · Cited by 69
“Pathophysiologic advances have enabled better management aimed at treating millions of SCD patients around the world, whereas bone marrow allografting [54 && ,80–82], and soon gene therapy [83], the sole treatments able to achieve definitive cure, are only available in wealthy countries.”
BackgroundSafe and Efficient Gene Therapy for Pyruvate Kinase Deficiency
García-Gómez, M., Calabria, A., García-Bravo, M., Benedicenti, F., Kosinski, P. A., López-Manzaneda, S., Hill, C., Mañú‐Pereira, M. D. M., Martín, M. A., Orman, I., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.87 · Cited by 65
“To determine whether hallmarks of insertional mutagenesis were present in transplanted mice, we assessed the occurrence of common insertion sites (CIS) similar to currently ongoing LV-mediated clinical trials.(10,11,13,14,27) CIS are insertional hotspots that may result from integration bias at the time of transductio…”
BackgroundMethodLiu, Y., Yang, Y., Kang, X., Lin, B., Qian, Y., Song, B., Gao, G., Chen, Y., Sun, X., Li, X., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.11.010 · Cited by 65
“Gene therapy has recently provided an alternative approach for b-thalassemia by permanent expression of the b-globin gene in patient-derived HSCs using a lentiviral vector, and these patients require no further blood transfusions.(4) The use of a viral vector has safety concerns for patients in that it may cause rando…”
MethodPseudotyping Lentiviral Vectors: When the Clothes Make the Virus
Duvergé, A., & Negroni, M. (2020) · Viruses · doi:10.3390/v12111311 · Cited by 70
“Besides treating the same diseases with these new vectors as are treated with γ-retroviral vectors mentioned above [27–31], β-thalassemia [32], Fanconi anemia [33], metachromatic leukodystrophy [34,35], mucopolysaccharidosis type I [36], adrenoleukodystrophy [37] and sickle cell disease [38] have also been made the ob…”
BackgroundGene Therapy for Hemoglobinopathies
Cavazzana, M., & Mavilio, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.122 · Cited by 70
“In the first patient who received gene therapy for b-thalassemia, the chicken HS4 enhancer in the BGI vector contained a cryptic signal that triggered abnormal splicing of the protooncogene HMG2A and a benign clonal dominance.(12) The element was removed for further clinical development.”
InfluentialHematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
“Cells 2022, 11, 1843 7 of 31 The first patients with SCD to participate in a gene therapy trial were part of the bluebird bio HGB-205 study receiving modified CD34+ cells transduced with the BB305 LV carrying the anti-sickling βT87Q-globin gene (NCT02151526).”
BackgroundInfluentialGalambrun, C., Pondarré, C., Bertrand, Y., Loundou, A., Bordigoni, P., Frange, P., Lutz, P., Mialou, V., Rubie, H., Socié, G., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.005 · Cited by 63
Self-citationYannaki, E., Karponi, G., Zervou, F., Constantinou, V., Bouinta, A., Tachynopoulou, V., Kotta, K., Jonlin, E. C., Papayannopoulou, T., Anagnostopoulos, Α., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.163 · Cited by 64
Morishima, T., Watanabe, K., Niwa, A., Hirai, H., Saida, S., Tanaka, T., Kato, I., Umeda, K., Hiramatsu, H., Saito, M. K., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.083873 · Cited by 63
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
Hudecek, M., & Ivics, Z. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.003 · Cited by 64
Fernández-García, M., Yañez, R. M., Sánchez‐Domínguez, R., Hernando-Rodríguez, M., Peces-Barba, M., Herrera, G., O’Connor, J., Segovia, J. C., Bueren, J. A., & Lamana, M. L. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0155-5 · Cited by 64
“conditioning regimens currently used in many HSC gene therapy protocols [36–39].”
BackgroundMethodWilliams, D. A., & Thrasher, A. J. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0206 · Cited by 56
Lentiviral Vector Induced Insertional Haploinsufficiency of Ebf1 Causes Murine Leukemia
Heckl, D., Schwarzer, A., Haemmerle, R., Steinemann, D., Rudolph, C., Skawran, B., Knoess, S., Krause, J., Li, Z., Schlegelberger, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.59 · Cited by 60
Optimal conditions for lentiviral transduction of engrafting human CD34+ cells
Uchida, N., Hsieh, M. M., Hayakawa, J., Madison, C., Washington, K. N., & Tisdale, J. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.63 · Cited by 57
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Rao, V. K., Kapp, D., & Schroth, M. K. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.12-a.s3 · Cited by 77
Ballas, S. K. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189002 · Cited by 69
RNA-guided retargeting of Sleeping Beauty transposition in human cells
Kovač, A., Miskey, C., Menzel, M., Grueso, E., Gogol‐Döring, A., & Ivics, Z. (2020) · eLife · doi:10.7554/elife.53868 · Cited by 64
Lamsfus‐Calle, A., Daniel-Moreno, A., Antony, J. S., Epting, T., Heumos, L., Baskaran, P., Admard, J., Casadei, N., Latifi, N., Siegmund, D. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66309-x · Cited by 65
Design and potential of non-integrating lentiviral vectors
Shaw, A., & Cornetta, K. (2014) · Biomedicines · doi:10.3390/biomedicines2010014 · Cited by 60
“For example, early clinical trials have shown evidence of disease correction or delay of onset including treatment for thalassemia, adrenoleukodystrophy, chronic lymphocytic leukemia, metachromatic leukodystrophy, and Wiskott Aldrich syndrome [9–13].”
BackgroundSelf-citationHuman artificial chromosome-based gene delivery vectors for biomedicine and biotechnology
Kouprina, N., Tomilin, A. N., Masumoto, H., Earnshaw, W. C., & Larionov, V. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.882314 · Cited by 60
“So far, the vast majority of gene therapy clinical trials have exploited viral vectors such as retroviral, lentiviral, adenoviral and adeno-associated virus-based vectors [7-22].”
BackgroundSuccessful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID
Garcia-Perez, L., van Eggermond, M., van Roon, L., Vloemans, S. A., Cordes, M., Schambach, A., Rothe, M., Berghuis, D., Lagresle-Peyrou, C., Cavazzana, M., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.016 · Cited by 56
“In the ALD trials there were some clones showing clonal dominance with over-representation of the insertion site near SMG6, CCND2, and HMGA2, but this has not led to development of leukemia and may be transient, as was reported for a SIN LV vector used for treating b-thalassemia.(53) In addition, our collective precli…”
MethodLentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Marquez Loza, L. I., Yuen, E. C., & McCray, P. B. (2019) · Genes · doi:10.3390/genes10030218 · Cited by 59
“One patient in the thalassemia trial developed a clonal expansion of a population, but it spontaneously regressed without treatment [139].”
BackgroundGene therapy matures in the clinic
Seymour, L. W., & Thrasher, A. J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2290 · Cited by 62
Boulad, F., Maggio, A., Wang, X., Moi, P., Acuto, S., Kogel, F., Takpradit, C., Prockop, S. E., Mansilla‐Soto, J., Cabriolu, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01554-9 · Cited by 69
Self-citationBiology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
Hendriks, R. W., Bredius, R. G., Pike-Overzet, K., & Staal, F. J. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.585971 · Cited by 59
“Successful treatment by SIN-LV mediated gene transfer of a patient with beta-thalessemia has been reported [126].”
BackgroundPaying for future success in gene therapy
Orkin, S. H., & Reilly, P. (2016) · Science · doi:10.1126/science.aaf4770 · Cited by 56
Río, P., Navarro, S., Güenechea, G., Sánchez‐Domínguez, R., Lamana, M. L., Yañez, R., Casado, J. A., Mehta, P. A., Pujol, R. M., Surrallés, J., et al. (2017) · Blood · doi:10.1182/blood-2017-03-774174 · Cited by 63
Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients
Díez, B., Genovese, P., Roman‐Rodriguez, F. J., Alvarez, L. A., Schiroli, G., Ugalde, L., Rodríguez, S., Sevilla, J., de Heredia, C. D., Holmes, M. C., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707540 · Cited by 64
“…these rare precursor cells are still far from transduction rates already achieved with gamma-retroviral and lentiviral vectors (Cartier et al, 2009; Cavazzana-Calvo et al, 2010; Aiuti et al, 2013; Biffi et al, 2013; Hacein-Bey-Abina et al, 2014) Consequently, clinical applications associated with…”
BackgroundThe old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
Thalassemias: from gene to therapy
Simone, G. D., Quattrocchi, A., Mancini, B., di Masi, A., Nervi, C., & Ascenzi, P. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101028 · Cited by 66
Witting, S. R., Vallanda, P., & Gamble, A. (2013) · Gene Therapy · doi:10.1038/gt.2013.23 · Cited by 61
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Blood · doi:10.1182/blood-2012-05-423210 · Cited by 55
Lévy, C., Amirache, F., Girard-Gagnepain, A., Frecha, C. A., Roman‐Rodriguez, F. J., Bernadin, O., Costa, C., Négre, D., Gutiérrez-Guerrero, A., Vranckx, L. S., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007773 · Cited by 60
Gene Therapy For Beta-Thalassemia: Updated Perspectives
Karponi, G., & Ζώγας, Ν. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s178546 · Cited by 60
Gene Therapy Approaches to Hemoglobinopathies
Ferrari, G., Cavazzana, M., & Mavilio, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.010 · Cited by 56
Coluccio, A., Miselli, F., Lombardo, A., Marconi, A., Malagoli Tagliazucchi, G., Gonçalves, M. A., Pincelli, C., Maruggi, G., Del Rio, M., Naldini, L., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.143 · Cited by 55
Insertional Oncogenesis by Non-Acute Retroviruses: Implications for Gene Therapy
Fan, H., & Johnson, C. (2011) · Viruses · doi:10.3390/v3040398 · Cited by 60
“One of the first trials has involved use of an HIV-based SIN vector expressing beta-globin to treat patients with beta-thalassemia [131].”
BackgroundThe Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy
Bernardo, M. E., & Aiuti, A. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.103 · Cited by 58
Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease
Uchida, N., Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., DiNicola, J., Shibata, Y., Hinds, M., Gudmundsdottir, B., Haro-Mora, J. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.022 · Cited by 55
Lipophosphonate/lipophosphoramidates: A family of synthetic vectors efficient for gene delivery
Berchel, M., Gall, T. L., Couthon‐Gourvès, H., Haelters, J., Montier, T., Midoux, P., Lehn, P., & Jaffrès, P. (2011) · Biochimie · doi:10.1016/j.biochi.2011.07.026 · Cited by 55
Song, L., Li, X., Jayandharan, G. R., Wang, Y., Aslanidi, G. V., Ling, C., Zhong, L., Gao, G., Yoder, M. C., Ling, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058757 · Cited by 54
“Indeed, recombinant lentiviral vectors were recently shown to mediate b-globin gene transfer and transgene expression in an adult patient with severe b-thalassemia, which led to transfusionindependence [1].”
BackgroundDevelopment of gene therapy for blood disorders: an update
Nienhuis, A. W. (2013) · Blood · doi:10.1182/blood-2013-04-453209 · Cited by 61
“Clonal dominance developed in 1 participant in a gene therapy trial for thalassemia and was associated with interruption of the HMGA2 gene by the vector genome resulting in the generation of a truncated messenger RNA with missing regulatory elements.(35) Gene therapy for immunodeficiencies”
BackgroundGene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors
Antony, J. S., Latifi, N., Haque, A. K. M. A., Lamsfus-Calle, A., Daniel-Moreno, A., Graeter, S., Baskaran, P., Weinmann, P., Mezger, M., Handgretinger, R., et al. (2018) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-018-0086-1 · Cited by 54
“Though the safety and efficacy of lentiviral-based gene therapy is positive in a treated patient, the transactivation of the proto-oncogene HMGA2 and more than 3500 unique integration sites in tested mouse model forewarns the possibility of insertional mutagenesis [2, 4].”
BackgroundGhaleh, H. E. G., Bolandian, M., Dorostkar, R., Jafari, A., & Pour, M. F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110276 · Cited by 61
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.